255 related articles for article (PubMed ID: 35104103)
1. In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.
Ye Z; Chen J; Zhao X; Li Y; Harmon J; Huang C; Chen J; Xu Q
ACS Biomater Sci Eng; 2022 Feb; 8(2):722-733. PubMed ID: 35104103
[TBL] [Abstract][Full Text] [Related]
2. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
[TBL] [Abstract][Full Text] [Related]
3. In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.
Miliotou AN; Papadopoulou LC
Methods Mol Biol; 2020; 2086():87-117. PubMed ID: 31707670
[TBL] [Abstract][Full Text] [Related]
4. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
5. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.
Ye B; Hu Y; Zhang M; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):185-191. PubMed ID: 36161298
[TBL] [Abstract][Full Text] [Related]
6. Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells.
Billingsley MM; Hamilton AG; Mai D; Patel SK; Swingle KL; Sheppard NC; June CH; Mitchell MJ
Nano Lett; 2022 Jan; 22(1):533-542. PubMed ID: 34669421
[TBL] [Abstract][Full Text] [Related]
7. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
8. CAR T cells produced in vivo to treat cardiac injury.
Rurik JG; Tombácz I; Yadegari A; Méndez Fernández PO; Shewale SV; Li L; Kimura T; Soliman OY; Papp TE; Tam YK; Mui BL; Albelda SM; Puré E; June CH; Aghajanian H; Weissman D; Parhiz H; Epstein JA
Science; 2022 Jan; 375(6576):91-96. PubMed ID: 34990237
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor therapy meets mRNA technology.
Wu J; Wu W; Zhou B; Li B
Trends Biotechnol; 2024 Feb; 42(2):228-240. PubMed ID: 37741706
[TBL] [Abstract][Full Text] [Related]
10. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.
Golubovskaya V; Sienkiewicz J; Sun J; Zhang S; Huang Y; Zhou H; Harto H; Xu S; Berahovich R; Wu L
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686170
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering.
Kitte R; Rabel M; Geczy R; Park S; Fricke S; Koehl U; Tretbar US
Mol Ther Methods Clin Dev; 2023 Dec; 31():101139. PubMed ID: 38027056
[TBL] [Abstract][Full Text] [Related]
12. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
Wang C; Zhang Y; Dong Y
Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.
Shin S; Lee P; Han J; Kim SN; Lim J; Park DH; Paik T; Min J; Park CG; Park W
Tissue Eng Regen Med; 2023 Jun; 20(3):371-387. PubMed ID: 36867402
[TBL] [Abstract][Full Text] [Related]
14. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
15. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.
Santoni M; Massari F; Montironi R; Battelli N
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188547. PubMed ID: 33932561
[TBL] [Abstract][Full Text] [Related]
16. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
17. Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell Lymphoma.
Álvarez-Benedicto E; Tian Z; Chatterjee S; Orlando D; Kim M; Guerrero ED; Wang X; Siegwart DJ
Angew Chem Int Ed Engl; 2023 Oct; 62(44):e202310395. PubMed ID: 37651468
[TBL] [Abstract][Full Text] [Related]
18. Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering.
Hamilton AG; Swingle KL; Joseph RA; Mai D; Gong N; Billingsley MM; Alameh MG; Weissman D; Sheppard NC; June CH; Mitchell MJ
Adv Healthc Mater; 2023 Dec; 12(30):e2301515. PubMed ID: 37602495
[TBL] [Abstract][Full Text] [Related]
19. mRNA-Laden Lipid-Nanoparticle-Enabled
Tang C; Jing W; Han K; Yang Z; Zhang S; Liu M; Zhang J; Zhao X; Liu Y; Shi C; Chai Q; Li Z; Han M; Wang Y; Fu Z; Zheng Z; Zhao K; Sun P; Zhu D; Chen C; Zhang D; Li D; Ni S; Li T; Cui J; Jiang X
ACS Nano; 2024 Jan; 18(3):2261-2278. PubMed ID: 38207332
[TBL] [Abstract][Full Text] [Related]
20. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
